...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Materials science & engineering >Cetuximab conjugated and doxorubicin loaded silica nanoparticles for tumor-targeting and tumor microenvironment responsive binary drug delivery of liver cancer therapy
【24h】

Cetuximab conjugated and doxorubicin loaded silica nanoparticles for tumor-targeting and tumor microenvironment responsive binary drug delivery of liver cancer therapy

机译：西妥昔单抗共轭和阿霉素负载的二氧化硅纳米颗粒用于肝癌治疗的肿瘤靶向和肿瘤微环境响应性二元药物递送

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In the present study, we successfully developed a preferable doxorubicin (Dox) loaded drug delivery system based on Cetuximab and silica nanoparticles (Cet-SLN/Dox). By employing the tumor homing property of Cetuximab and the drug-loading capability of silica nanoparticles, the prepared Cet-SLN/Dox was able to load Dox to achieve the co-delivery of two drugs (Cetuximab and Dox). In vitro analysis revealed that Cet-SLN/Dox was nano-sized particles with decent drug loading capabilities and smart drug release profile. Further studies demonstrated that Cet-SLN/Dox was superior in tumor-homing and anti-cancer efficiency than Cetuximab free SLN/Dox and free Dox, possibly due to EGFR mediated endocytosis and the combined anti-cancer effects of Cetuximab and Dox within Cet-SLN/Dox.
机译：在本研究中，我们成功开发了一种基于西妥昔单抗和二氧化硅纳米颗粒（Cet-SLN / Dox）的优选装载阿霉素（Dox）的药物递送系统。通过利用西妥昔单抗的肿瘤归巢特性和二氧化硅纳米颗粒的载药能力，制得的Cet-SLN / Dox能够载载Dox来实现两种药物（西妥昔单抗和Dox）的共同递送。体外分析显示，Cet-SLN / Dox是具有适当载药能力和智能药物释放曲线的纳米级颗粒。进一步的研究表明，Cet-SLN / Dox在肿瘤归巢和抗癌功效方面优于不含西妥昔单抗的SLN / Dox和游离Dox，这可能是由于EGFR介导的内吞作用以及西妥昔单抗和Dox在Cet- SLN / Dox。

著录项

  • 来源
    《Materials science & engineering》 |2017年第7期|944-950|共7页
  • 作者

    Jia-kang Wang; Yu-ying Zhou; Shu-jun Guo; Ya-yu Wang; Chang-jun Nie; Hai-long Wang; Jia-lang Wang; Ying Zhao; Xiao-yan Li; Xiao-jia Chen;

  • 作者单位

    Cancer Center of Guangzhou Medical University, Guangzhou, China;

    Institute of Biomedicine &Department of Cell Biology, Jinan University National Engineering Research Center of Genetic Medicine, Guangdong Provincial Key Laboratory of Bioengineering Medicine, Guangzhou, China;

    Institute of Biomedicine &Department of Cell Biology, Jinan University National Engineering Research Center of Genetic Medicine, Guangdong Provincial Key Laboratory of Bioengineering Medicine, Guangzhou, China;

    Institute of Biomedicine &Department of Cell Biology, Jinan University National Engineering Research Center of Genetic Medicine, Guangdong Provincial Key Laboratory of Bioengineering Medicine, Guangzhou, China;

    Institute of Biomedicine &Department of Cell Biology, Jinan University National Engineering Research Center of Genetic Medicine, Guangdong Provincial Key Laboratory of Bioengineering Medicine, Guangzhou, China;

    Institute of Biomedicine &Department of Cell Biology, Jinan University National Engineering Research Center of Genetic Medicine, Guangdong Provincial Key Laboratory of Bioengineering Medicine, Guangzhou, China;

    Cancer Center of Guangzhou Medical University, Guangzhou, China;

    Institute of Biomedicine &Department of Cell Biology, Jinan University National Engineering Research Center of Genetic Medicine, Guangdong Provincial Key Laboratory of Bioengineering Medicine, Guangzhou, China;

    Institute of Biomedicine &Department of Cell Biology, Jinan University National Engineering Research Center of Genetic Medicine, Guangdong Provincial Key Laboratory of Bioengineering Medicine, Guangzhou, China;

    Institute of Biomedicine &Department of Cell Biology, Jinan University National Engineering Research Center of Genetic Medicine, Guangdong Provincial Key Laboratory of Bioengineering Medicine, Guangzhou, China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Cetuximab; Silica nanoparticles; Doxorubicin; Liver cancer;

    机译：西妥昔单抗;二氧化硅纳米粒子;阿霉素肝癌;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号